Drug Profile
Filgrastim biosimilar - Harvest Moon Pharmaceuticals
Alternative Names: G-CSF biosimilar - Harvest Moon PharmaceuticalsLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 15 Feb 2016 No recent reports on development identified - Phase-III for Neutropenia in European Union (Parenteral)
- 15 Feb 2016 No recent reports on development identified - Phase-III for Neutropenia in USA (Parenteral)
- 22 Aug 2013 Phase-III clinical trials in Neutropenia in USA and EU (Parenteral)